In this trial, the efficacy of potential predictive biomarkers was also investigated: the presence of a T cell-inflamed gene-expression profile, PD-L1 expression and higher tumor mutational burden (TMB) resulted the best predictors of responses among the different types of solid tumors. This evidence concerns the gene CD274 and neoplasm.